AA
FATE icon

ALPS Advisors’s Fate Therapeutics FATE Stock Holding History

ALPS Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-52,950
Closed -$1.19M – 1048
2022
Q3 		$1.19M Sell
52,950
-4,370
-8% -$126K 0.01% 414
2022
Q2 		$1.42M Buy
+57,320
New +$1.58M 0.01% 376
2021
Q2 		– Sell
-130,688
Closed -$10.8M – 909
2021
Q1 		$10.8M Buy
130,688
+6,320
+5% +$606K 0.11% 142
2020
Q4 		$11.3M Buy
124,368
+13,621
+12% +$846K 0.13% 140
2020
Q3 		$4.43M Buy
110,747
+4,768
+4% +$166K 0.07% 167
2020
Q2 		$3.64M Sell
105,979
-31,454
-23% -$937K 0.05% 179
2020
Q1 		$3.05M Sell
137,433
-14,724
-10% -$372K 0.05% 178
2019
Q4 		$2.98M Buy
152,157
+21,771
+17% +$346K 0.02% 195
2019
Q3 		$2.02M Sell
130,386
-6,048
-4% -$116K 0.02% 209
2019
Q2 		$2.77M Sell
136,434
-19,404
-12% -$350K 0.02% 197
2019
Q1 		$2.74M Buy
155,838
+6,735
+5% +$106K 0.02% 196
2018
Q4 		$1.91M Buy
149,103
+54,571
+58% +$761K 0.01% 224
2018
Q3 		$1.54M Buy
94,532
+17,818
+23% +$211K 0.01% 288
2018
Q2 		$870K Buy
+76,714
New +$845K 0.01% 364

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ALPS Advisors's FATE Position: Q4 2022 in Review

ALPS Advisors sold out of Fate Therapeutics (FATE) in Q4 2022, closing a stake of 52,950 shares — an estimated $1.19M sold.

ALPS Advisors first reported a position in FATE in Q2 2018 and held it in 14 quarters. The position peaked at $11.3M in Q4 2020. 227 funds tracked by Wall St. Rank hold FATE as of Q4 2022.

  • ALPS Advisors reported no remaining Fate Therapeutics position as of Q4 2022 after selling out during the quarter.
  • ALPS Advisors sold 52,950 Fate Therapeutics shares in Q4 2022, an estimated $1.19M.
  • ALPS Advisors first reported a position in Fate Therapeutics in Q2 2018 and held it in 14 quarters.
  • ALPS Advisors's Fate Therapeutics position peaked at $11.3M in Q4 2020.
  • 227 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2022.

Based on ALPS Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.